Literature summary for 3.5.4.1 extracted from

Kaliberov, S.A.; Markert, J.M.; Gillespie, G.Y.; Krendelchtchikova, V.; Della Manna, D.; Sellers, J.C.; Kaliberova, L.N.; Black, M.E.; Buchsbaum, D.J.
Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma (2007), Gene Ther., 14, 1111-1119.

Search for more literature for 3.5.4.1

Cloned(Commentary)

Cloned (Comment)	Organism
development of an adenoviral vector for enzyme expression in cancer treatment by gene therapy, expression of the enzyme mutant D134A using this vector in human glioma cell lines D54MG, U87MG, and U251MG	Escherichia coli

Protein Variants

Protein Variants	Comment	Organism
D134A	site-directed mutagenesis, the mutant enzyme shows a higher affinity for cytosine than the wild-type enzyme	Escherichia coli

Organism

Organism	UniProt	Comment	Textmining
Escherichia coli	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
5-fluorocytosine + H2O	activation of the prodrug to the cytotoxic drug in cancer therapy by recombinant adenoviral vector expressed enzyme in human glioma cells, leads to increased 5-fluorouracil-mediated cell killing, overview	Escherichia coli	5-fluorouracil + NH3	-	?

Temperature Optimum [°C]

Temperature Optimum [°C]	Temperature Optimum Maximum [°C]	Comment	Organism
37	-	in vivo assay at	Escherichia coli

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)